High-density lipoprotein cholesterol levels and prognosis in non-ischemic dilated cardiomyopathy
-
By
-
Chao Gong
-
Mengmeng Zhou
-
Shenzhen Gong
-
Chunxiao Liu
-
Jinying Zhang
-
June 26, 2026
-
Clinical Scorecard: Association of High-Density Lipoprotein Cholesterol Levels with Outcomes in Non-Ischemic Dilated Cardiomyopathy
At a Glance
| Category | Detail |
|---|
| Condition | Non-Ischemic Dilated Cardiomyopathy (DCM) |
| Key Mechanisms | Association between HDL-C levels and clinical outcomes in DCM. |
| Target Population | Patients diagnosed with non-ischemic DCM. |
| Care Setting | Retrospective cohort study in a hospital setting. |
Key Highlights
- Lower HDL-C levels are independently associated with increased risk of adverse outcomes in DCM.
- Higher HDL-C correlates with better event-free survival for mortality and heart transplantation.
- The association between HDL-C and outcomes is partially attenuated by pulmonary hypertension markers.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of DCM based on impaired left ventricular ejection fraction and elevated left ventricular end-diastolic dimension.
Management
- Consider HDL-C levels in risk stratification for patients with DCM.
Monitoring & Follow-up
- Monitor HDL-C levels as a potential prognostic biomarker in DCM.
Risks
- Lower HDL-C levels are associated with increased risk of all-cause mortality and heart failure readmission.
Patient & Prescribing Data
297 patients with non-ischemic DCM.
HDL-C may serve as a prognostic biomarker to inform treatment decisions.
Clinical Best Practices
- Utilize HDL-C levels in conjunction with other clinical assessments for comprehensive risk evaluation.
- Adjust for pulmonary hypertension when interpreting HDL-C's prognostic value.
Related Resources & Content
